Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P78381
UPID:
S35A2_HUMAN
Alternative names:
Solute carrier family 35 member A2; UDP-galactose transporter
Alternative UPACC:
P78381; A8K2L9; A8K9V1; B4DE11; B4DPT2; E7EW45; Q8IV21; Q92553
Background:
The UDP-galactose translocator, also known as Solute carrier family 35 member A2, plays a pivotal role in cellular functions by transporting UDP-galactose into the Golgi apparatus. This process is essential for the synthesis of globotriaosylceramide, a key component in cell membranes, highlighting its importance in cellular architecture and signaling.
Therapeutic significance:
Linked to the severe neurologic disorder, Congenital disorder of glycosylation 2M, the UDP-galactose translocator's dysfunction underscores its critical role in human health. Understanding the role of UDP-galactose translocator could open doors to potential therapeutic strategies, offering hope for treating this debilitating condition.